CWM
MRNS

Catamount Wealth Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Catamount Wealth Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-125
Closed -$5K – 232
2018
Q3 		$5K Hold
125
– – ﹤0.01% 166
2018
Q2 		$3K Buy
+125
New +$2.77K ﹤0.01% 173

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Catamount Wealth Management's MRNS Position: Q4 2018 in Review

Catamount Wealth Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2018, closing a stake of 125 shares — an estimated $5K sold.

Catamount Wealth Management first reported a position in MRNS in Q2 2018 and held it in 2 quarters. The position peaked at $5K in Q3 2018. 90 funds tracked by Wall St. Rank hold MRNS as of Q4 2018.

  • Catamount Wealth Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Catamount Wealth Management sold 125 Marinus Pharmaceuticals, Inc shares in Q4 2018, an estimated $5K.
  • Catamount Wealth Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 2 quarters.
  • Catamount Wealth Management's Marinus Pharmaceuticals, Inc position peaked at $5K in Q3 2018.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2018.

Based on Catamount Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.